BTIG cuts PulteGroup stock price target to $145

DraftKings price target raised to $59 from $55 at BTIG
BTIG analyst Clark Lampen raised the firm’s price target on DraftKings (DKNG) to $59 from $55 and keeps a Buy rating on the shares as part of a
IDEXX stock price target raised to $530 at BTIG
BTIG analyst Mark Massaro announced an increased price target for IDEXX Laboratories (NASDAQ:IDXX), raising it from $500 to $530, while maintaining a Buy rating on the stock. The revision follows IDEXX's Q4 performance,
PulteGroup price target lowered to $145 from $156 at BTIG
BTIG lowered the firm’s price target on PulteGroup (PHM) to $145 from $156 and keeps a Buy rating on the shares. The company’s EPS beat was
Boot Barn price target raised to $200 from $190 at BTIG
BTIG raised the firm’s price target on Boot Barn (BOOT) to $200 from $190 and keeps a Buy rating on the shares. The company’s Q3 results were
BTIG cuts PulteGroup stock price target to $145 from $156
BTIG analyst Carl Reichardt Jr. revised the price target on PulteGroup (NYSE:PHM) stock to $145.00, down from the previous $156.00, while maintaining a Buy rating on the shares. The adjustment follows PulteGroup's fourth-quarter earnings report,
BTIG raises PennyMac Financial target to $135, maintains Buy rating
BTIG analyst Eric Hagen adjusted the price target for PennyMac Financial Services, Inc. (NYSE:PFSI), increasing it to $135 from the previous $115 while reaffirming a Buy rating on the stock. The stock is currently trading near its 52-week high of $119.
BTIG cuts IQVIA stock rating to neutral amid sector headwinds
BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...
Iqvia downgraded to Neutral from Buy at BTIG
BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...
BTIG Research Estimates D.R. Horton’s Q4 Earnings (NYSE:DHI)
Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note ...
Semiconductor selloff was in the charts, says BTIG's Krinsky
What damage might Monday's ongoing selloff do to the technical set-up for stocks? Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already sug ...
InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...
medtechdive7d
Doctors expect Boston Scientific to lead PFA race, survey finds
Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...
Seeking Alpha20d
BTIG cuts rating on Match Group as Tinder turnaround looks bleak
Analysts at BTIG moved to the sidelines on online dating apps company Match Group (NASDAQ:MTCH) and lowered its investment rating to "Neutral" from "Buy" on Tuesday. The research firm said its ...
HOPE Therapeuticstm, Inc. And Nrx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG As Financial Advisor
The Company has recently announced execution of an agreement for $27 million in funding for HOPE <a target=_blank href= ...
BTIG maintains Neutral on NVR stock, trims EPS estimates
BTIG analyst Carl Reichardt Jr. maintained a Neutral rating on shares of NVR Inc . (NYSE:NVR), while slightly lowering ...